GEHC logo

GE HealthCare Technologies Inc. Stock Price

NasdaqGS:GEHC Community·US$33.9b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 105 Fair Values set on narratives written by author

GEHC Share Price Performance

US$74.30
-13.87 (-15.73%)
14.6% undervalued intrinsic discount
US$86.96
Fair Value
US$74.30
-13.87 (-15.73%)
14.6% undervalued intrinsic discount
US$86.96
Fair Value
Price US$74.30
AnalystConsensusTarget US$86.96

GEHC Community Narratives

AnalystConsensusTarget·
Fair Value US$86.96 14.6% undervalued intrinsic discount

New IDN Partnerships And Advanced Imaging Will Unlock Future Markets

1users have liked this narrative
0users have commented on this narrative
55users have followed this narrative
US$86.96
14.6% undervalued intrinsic discount
Revenue growth
4.38% p.a.
Profit Margin
11.06%
Future PE
19.89x
Share price in 2028
US$109.62

Snowflake Analysis

Undervalued with solid track record.

1 Risk
4 Rewards

GE HealthCare Technologies Inc. Key Details

US$20.2b

Revenue

US$12.0b

Cost of Revenue

US$8.3b

Gross Profit

US$6.0b

Other Expenses

US$2.2b

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
4.86
40.80%
10.95%
100.6%
View Full Analysis

About GEHC

Founded
2022
Employees
53000
CEO
Peter Arduini
WebsiteView website
www.gehealthcare.com

GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, X-ray systems, and women’s health products. The AVS segment provides ultrasound, image guided therapies, and interventional solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as women’s health, cardiovascular, and comprehensive care ultrasound as well as surgical visualization and guidance products. The PCS segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring, diagnostic cardiology, consumables and services, digital solutions, maternal infant care, and anesthesia products. The PDx segment supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, and positron emission tomography to the radiology and nuclear medicine industries. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. The company was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.

Recent GEHC News & Updates

Recent updates

No updates